These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29907486)

  • 1. Imaging of Tumor Characteristics and Molecular Pathways With PET: Developments Over the Last Decade Toward Personalized Cancer Therapy.
    Marcu LG; Moghaddasi L; Bezak E
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1165-1182. PubMed ID: 29907486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET-Based Personalized Management in Clinical Oncology: An Unavoidable Path for the Foreseeable Future.
    Basu S; Alavi A
    PET Clin; 2016 Jul; 11(3):203-7. PubMed ID: 27321025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging hypoxia and angiogenesis in tumors.
    Rajendran JG; Krohn KA
    Radiol Clin North Am; 2005 Jan; 43(1):169-87. PubMed ID: 15693655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging requirements for personalized medicine: the oncologists point of view.
    Kruse V; Belle SV; Cocquyt V
    Curr Pharm Des; 2014; 20(14):2234-49. PubMed ID: 24025098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular imaging of targeted therapies with positron emission tomography: the visualization of personalized cancer care.
    Mammatas LH; Verheul HM; Hendrikse NH; Yaqub M; Lammertsma AA; Menke-van der Houven van Oordt CW
    Cell Oncol (Dordr); 2015 Feb; 38(1):49-64. PubMed ID: 25248503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET-based molecular imaging in personalized oncology: potential of the assessment of therapeutic outcome.
    Dimitrakopoulou-Strauss A
    Future Oncol; 2015; 11(7):1083-91. PubMed ID: 25804123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET imaging to monitor cancer therapy.
    Malviya G; Nayak TK
    Curr Pharm Biotechnol; 2013; 14(7):669-82. PubMed ID: 24372238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers.
    Pantel AR; Mankoff DA
    Cancer Lett; 2017 Feb; 387():25-31. PubMed ID: 27195912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET of signal transduction pathways in cancer.
    Holland JP; Cumming P; Vasdev N
    J Nucl Med; 2012 Sep; 53(9):1333-6. PubMed ID: 22879078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlating and Combining Genomic and Proteomic Assessment with In Vivo Molecular Functional Imaging: Will This Be the Future Roadmap for Personalized Cancer Management?
    Basu B; Basu S
    Cancer Biother Radiopharm; 2016 Apr; 31(3):75-84. PubMed ID: 27093341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positron emission tomography tracers for imaging angiogenesis.
    Haubner R; Beer AJ; Wang H; Chen X
    Eur J Nucl Med Mol Imaging; 2010 Aug; 37 Suppl 1(0 1):S86-103. PubMed ID: 20559632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron emission tomography imaging of cancer biology: current status and future prospects.
    Chen K; Chen X
    Semin Oncol; 2011 Feb; 38(1):70-86. PubMed ID: 21362517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging of Tumor Metabolism Using Positron Emission Tomography (PET).
    Apostolova I; Wedel F; Brenner W
    Recent Results Cancer Res; 2016; 207():177-205. PubMed ID: 27557539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia and tumor metabolism in radiation oncology: targets visualized by positron emission tomography.
    Wijsman R; Kaanders JH; Oyen WJ; Bussink J
    Q J Nucl Med Mol Imaging; 2013 Sep; 57(3):244-56. PubMed ID: 24045621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multimodality Imaging in Tumor Angiogenesis: Present Status and Perspectives.
    Niccoli Asabella A; Di Palo A; Altini C; Ferrari C; Rubini G
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28846661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).
    Yuan H; Schroeder T; Bowsher JE; Hedlund LW; Wong T; Dewhirst MW
    J Nucl Med; 2006 Jun; 47(6):989-98. PubMed ID: 16741309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Current and Evolving Role of PET in Personalized Management of Lung Cancer.
    Mena E; Yanamadala A; Cheng G; Subramaniam RM
    PET Clin; 2016 Jul; 11(3):243-59. PubMed ID: 27321029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Positron emission tomography and evaluation of response to targeted therapies].
    Gauthier H
    Bull Cancer; 2009 Nov; 96(11):1087-97. PubMed ID: 19875353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid dual-tracer PTSM+ATSM PET imaging of tumour blood flow and hypoxia: a simulation study.
    Rust TC; Kadrmas DJ
    Phys Med Biol; 2006 Jan; 51(1):61-75. PubMed ID: 16357431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current preclinical and clinical applications of hypoxia PET imaging using 2-nitroimidazoles.
    Peeters SG; Zegers CM; Yaromina A; Van Elmpt W; Dubois L; Lambin P
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):39-57. PubMed ID: 25517080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.